Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life1 and infusion-related reactions (IRR) in patients with lymphatic cancers.2
EHA 2024 took place in Madrid, Spain from June 13 to 16, 2024. | Image credit: Anusorn - stock.adobe.com
In the first study, the researchers looked at how quality of life was informed by biosimilar rituximab therapy.1
The treatment of hematologic malignancies has led to significant advancements in survival rates and patient outcomes. However, the impact of these treatments on the quality of life (QOL) of patients remains a critical concern. QOL encompasses a wide range of patient experiences, including physical, functional, emotional, and social well-being. In hematologic malignancies, the disease and its treatment can profoundly affect various aspects of a patient's life.
According to the authors, the QOL measure is crucial for understanding the challenges faced by individuals with hematologic diseases, emphasizing the need for patient-centered care strategies to improve overall support and outcomes.
The primary aim of this study was to investigate the QOL of patients undergoing treatment for hematologic malignancies and uncover critical areas where interventions are needed to improve overall QOL. The multicenter study was conducted across 13 onco-hematology units in eight Italian regions, focusing on adults diagnosed with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) who received rituximab treatment between March 2018 and June 2022. Patient-reported data were collected using the FACT-Lym questionnaire at the third drug infusion to assess Health-Related Quality of Life (HRQOL) across various domains in individuals with B-cell malignancies.
Researchers included 430 participants (n = 249 male; most were aged 65-75 years). The majority of participants were diagnosed with NHL (90%), followed by CLL (6.3%) and other hematological diseases (3.72%).
The findings suggested that although participants generally report an acceptable QOL across multiple dimensions, functional well-being is the most compromised aspect. Emotional, social, and physical well-being are less adversely affected on average. The researchers noted that pattern indicates the nuanced impact of treatment on different life areas, highlighting the importance of addressing specific domains to enhance overall patient care.
Participants with NHL and CLL reported similar QOL scores, with those with CLL faring slightly better in physical and lymphoma-specific well-being. Individuals with other hematological conditions generally reported lower scores in several domains, indicating a need for targeted interventions to address their QOL.
The other study found that the rate of IRRs as a result of treating patients with chronic lymphoproliferative disorders (cLPDs) with rituximab biosimilars was comparable with previously published data, with no observed differences between the 2 biosimilars studied.
A study was conducted to assess the frequency and severity of IRRs associated with the rituximab biosimilars Rixathon and Blitzima in patients with a cLPD treated at the Clinic for Hematology, University Clinical Center of Serbia from 2020 to 2022. Medical records of 200 patients were analyzed to identify associations between IRR occurrence and various clinical, radiographic, and therapeutic features, and to compare IRR frequencies between different cLPD entities and the 2 rituximab biosimilars. All patients received premedication with methylprednisolone, paracetamol, and loratadine.
IRRs occurred in 71% of patients, particularly during their first infusion. The authors said that a small percentage of patients may need to discontinue rituximab due to serious IRRs, and they observed a low incidence of fatal outcomes (0.07%).
The occurrence of IRRs was not dependent on gender, age, clinical stage, disease localization (extranodal vs nodal), presence of “B” symptoms, bulky mass, Eastern Cooperative Oncology Group performance status, type of adjunct chemotherapy, or the timing of rituximab administration (first cycle vs second cycle and onward).
Patients with diffuse large B-cell lymphoma (DLBCL) exhibited significantly fewer IRRs compared with those with CLL (15% vs 34%; P = .045). Additionally, patients treated in second or later therapeutic lines experienced more IRRs compared with those in the first treatment line (P = .0233). Factors such as arterial hypertension (AH), type 2 diabetes (T2D), coronary artery disease, and smoking did not influence IRR occurrence.
In the subgroup of patients with DLBCL (n = 67), those with AH experienced IRRs more frequently (P = .014). Among patients with CLL (n = 76), those with AH and T2D showed a higher frequency of IRRs (P = .005 and .041, respectively).
References
1. Masnata LJ, Urru S, Alegiani SS, Mayer F, Campomori A. Quality of life (QOL) in patients with hematologic malignancies receiving rituximab biosimilars: results from a real-world setting. Presented at EHA 2024; June 13-16, 2024; Madrid, Spain. Abstract P1689. https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eha/temp/eha24_abstract_bodies/P1689.pdf
2. Vukovic V, Karan-Đurašević T, Pesic A, et al. Infusion-related reactions in patients with chronic lymphoproliferative disorders treated with two rituximab biosimilars: single center experience. Presented at EHA 2024; June 13-16, 2024; Madrid, Spain. Abstract PB3059. https://s3.eu-central-1.amazonaws.com/m-anage.com.storage.eha/temp/eha24_abstract_bodies/PB3059.pdf
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
Addressing Patent Abuse, Reimbursement Models Key to Sustainable Biosimilar Market
April 25th 2025Sonia T. Oskouei, PharmD, emphasized strategies to streamline regulations and evolve to overcome barriers and expand the availability of cost-effective biosimilar treatments across more therapeutic areas.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Decade of Biosimilars Yields $36 Billion in Savings and Strengthens Supply Chain
April 24th 2025Dracey Poore, MS, director of biosimilars and emerging therapies at Cardinal Health, highlighted that biosimilars saved $36 billion over the last decade by improving patient access and the supply chain, but continued education and a robust pipeline are crucial for future growth.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Latest Biosimilar Deals Signal Growth Across Immunology, Oncology Markets
April 14th 2025During Q1 2025, pharmaceutical companies accelerated biosimilar expansion through strategic acquisitions and partnerships in hopes of boosting patient access to lower-cost treatments in immunology and oncology.
2 Commerce Drive
Cranbury, NJ 08512